West Pharmaceutical Services, Inc. WST
Healthcare · Medical Instruments & Supplies · United States · S&P 500
Based on the available data, West Pharmaceutical Services, Inc. gets an algorithmic score of 69/100. It trades at 376.63 $, with a bullish technical trend (RSI 67.2) and 33.4% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
- Low beta (0.66): defensive profile.
- Meaningful dividend (23.00%).
Weaknesses
- —
Fundamentals
| P/E | 48.16 |
| Forward P/E | 37.73 |
| PEG | 3.10 |
| P/B | 8.87 |
| EV/EBITDA | 28.93 |
| P/S | 7.97 |
| ROE % | 19.09 |
| ROA % | 11.38 |
| Gross margin % | 36.79 |
| Operating margin % | 22.47 |
| Net margin % | 16.98 |
| Revenue growth % (y/y) | 13.80 |
| Earnings growth % (y/y) | 18.10 |
| Revenue CAGR % | 2.12 |
| Earnings CAGR % | -5.55 |
| Debt/Equity % | 10.59 |
| Current ratio | 2.82 |
| FCF yield % | 1.77 |
| Dividend yield % | 23.00 |
| Payout % | 11.14 |
Returns
| 1 month | +11.6 % |
| 3 months | +5.0 % |
| 6 months | +53.9 % |
| YTD | +36.6 % |
| 1 year | +44.5 % |
| 3 years | +2.0 % |
| 5 years | -14.8 % |
Risk
| 1-year volatility | 33.4 % |
| Beta | 0.66 |
| 5-year max drawdown | -59.3 % |
| Sharpe 1A | 1.15 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.